Disney (DIS) ESPN Subscriber Count Lower than Expectations; Stifel Reiterates Buy

Upside from Force Awakens Plus Coming Sequel Could Mean 35% EPS Upside for Disney (DIS) - FBR

December 1, 2015 6:48 AM EST

FBR Capital analyst, Barton Crockett, sees 35% EPS upside for Disney (NYSE: DIS) as "Star Wars: Force Awakens" appears to be tracking to $1 billion in box office receipts. What may not be considered in expectations is the coming sequel, one year from now: "Rogue One", due in December 2016. As Force Awakens beats expectations, projections for Rogue One... More

Disney's (DIS) 10-K Shows 3% ESPN Sub Decline; Nomura Securities Reiterates Buy

November 30, 2015 10:23 AM EST

Nomura Securities reiterated a Buy rating and $121.00 price target on Walt Disney (NYSE: DIS) following the release of the company's FY15 10-K. The 10-K outlined that FY15 Media Network revenue growth was largely driven by 8% YoY growth in affiliate rate increases. However, the... More

Walt Disney (DIS) Sub Loss Disclosures Not New News - Wells Fargo

November 30, 2015 9:06 AM EST

Wells Fargo analyst, Marci Ryvicker, stated that the sub losses disclosed in Walt Disney (NYSE: DIS) 10-K is not new information and that the lost profit may be less than professional investors expect.

Disney's 10-K shows 3MM sub losses for ESPN and 2MM... More

Two-decade Pfizer mission pays off for Guggenheim's deal king

November 26, 2015 2:48 PM EST

By Pamela Barbaglia and Mike Stone

LONDON/NEW YORK (Reuters) - Alan Schwartz knows how to play a long game. The executive chairman of boutique investment bank Guggenheim Partners spent almost 20 years cultivating Pfizer (NYSE: PFE) boss Ian Read as a client. His strategy paid off handsomely when Guggenheim was named lead adviser for one of the biggest deals in history - Viagra-maker Pfizer's $160 billion acquisition of Botox-maker Allergan (NYSE: AGN).

Schwartz, 65, had been working with Read since 2013 to find a European-registered... More